Here’s a taste of what participants in this year’s virtual annual meeting, ACR Convergence 2020, will have access to during Down & Dirty 30, four 30-minute sessions designed to provide refreshers on specific rheumatology-related topics.
Targeted Vertebral Fracture Assessment
A Canadian study sought to identify individuals at high fracture risk and provide them with pharmacotherapy to prevent fractures. They found the assessment of hip and lumbar dual-energy X-ray absorptiometry scans for vertebral fracture can be useful in the identification of women and men aged 70 years and older who should qualify for anti-osteoporosis treatment…
Staying Connected with Constituents During COVID-19
Legislative staff talk about working during the pandemic and how they are connecting with constituents.
Out-of-Pocket Costs for Patients with Rheumatic Diseases Skyrocket
An estimated one in four American adults live with a rheumatic disease, and according to a new national patient survey by the ACR, the healthcare and lifestyle challenges have become worse for these patients during the COVID-19 pandemic. Key survey findings include: Patients currently seeing a rheumatologist declined 52% between 2019 and 2020; 68% of…
2021 Merit-Based Incentive Payment System Payment Adjustments, Explained
Many clinicians are receiving smaller reimbursements than expected for their 2021 Merit-Based Incentive Payment System adjustments. Available funding is extremely limited due to the high number of clinicians who were unable to report 2019 MIPS data and accepted the automatic neutral payment under the extreme and uncontrollable circumstances policy.
Guidance Coming for Anticipated COVID-19 Vaccine
What to vaccinate for and when to do so are challenges for rheumatologists and rheumatology professionals under normal circumstances. During the COVID-19 pandemic, even more questions are being raised, specifically regarding a possible vaccine for SARS-CoV-2. The ACR’s COVID-19 Practice and Advocacy Task Force is working on a guidance document to help ACR members address these pressing questions.
Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19
NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1 For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and…
Study Provides Clues to Undefined, Systemic, Autoinflammatory Diseases
A study from October 2019 describes the clinical characteristics of pediatric patients with undefined systemic autoinflammatory diseases. Researchers conducted a genetic analysis and outlined specific variants. They found patients with pericarditis and intellectual impairment may have distinct clinical phenotypes, which may lead to improved diagnostic and treatment options.
Pharmacists Not Required to Substitute Generics for Brand-Name Drugs in Most U.S. States
(Reuters Health)—Only 19 U.S. states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available, with the 31 remaining states allowing but not requiring these substitutions, a new study finds. Researchers examined laws on the books as of September 2019 pertaining to generic substitution of small molecule drugs, as well as…
After COVID-19-Associated MIS-C, Immune Changes Resolve
NEW YORK (Reuters Health)—A new study of multisystem inflammatory syndrome in children (MIS-C) shows that the immune system is profoundly altered during acute illness, but gradually returns back to normal. MIS-C is distinct from both COVID-19 and Kawasaki disease, but is associated with previous SARS-CoV-2 infection, the immunological profiling study reveals. Dr. Manu Shankar-Hari, an…
- « Previous Page
- 1
- …
- 185
- 186
- 187
- 188
- 189
- …
- 816
- Next Page »